Is The Aids News As Good As It Looks?
At last, the AIDS virus may be in retreat. In the past two years, companies have developed drugs powerful enough to render a patient's blood virtually virus-free. With the bug held in check, victims have seen remarkable recoveries in their ravaged immune systems. Death rates and hospital admissions for the myriad infections that accompany AIDS are plunging, at least in countries rich enough to afford the treatments, which can cost as much as $15,000 annually for each patient.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.